Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
Biotech
INmune flunks Alzheimer’s trial, focuses on subgroup efficacy
A phase 2 study of INmune Bio’s TNF inhibitor in Alzheimer’s disease has missed its primary endpoint, wiping 60% off the biotech share price.
Nick Paul Taylor
Jun 30, 2025 8:50am
GE HealthCare's PET agent Vizamyl expands reach in Alzheimer's
Jun 27, 2025 9:45am
NewAmsterdam links lipid drug to drop in Alzheimer's biomarker
Jun 9, 2025 8:25am
Sanofi inks $470M Vigil buyout to snag Alzheimer's prospect
May 22, 2025 4:49am
FDA clears its first blood test for diagnosing Alzheimer's
May 16, 2025 4:30pm
CEO invests own cash to move NKGen toward Alzheimer’s readout
May 8, 2025 10:22am
